Login to Your Account

Genticel Gets $24M for Therapeutic HPV Vaccine

By Cormac Sheridan
Staff Writer

Thursday, April 25, 2013
Genticel SA raised €18.2 million (US$23.6 million) in a Series C round led by Wellington Partners, to move ProCervix, its bivalent therapeutic vaccine for combating human papillomavirus (HPV) infection into Phase II trials.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription